Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Acute Lymphoblastic Leukemia JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Alvarnas, J. C., Brown, P. A., Aoun, P., Ballen, K. K., Bellam, N., Blum, W., Boyer, M. W., Carraway, H. E., Coccia, P. F., Coutre, S. E., Cultrera, J., Damon, L. E., DeAngelo, D. J., Douer, D., Frangoul, H., Frankfurt, O., Goorha, S., Millenson, M. M., O'Brien, S., Petersdorf, S. H., Rao, A. V., Terezakis, S., Uy, G., Wetzler, M., Zelenetz, A. D., Naganuma, M., Gregory, K. M. 2012; 10 (7): 858-913

Abstract

The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations. It is recommended that patients be treated at specialized centers with expertise in the management of ALL.

View details for Web of Science ID 000306303900009

View details for PubMedID 22773801